“Pancreatic cancer: Dr. Pudlarz praises 'new generation targeted therapy' that inhibits gen” — what this page in the network covers. Pudlarz praises 'new generation targeted therapy' that inhibits gene mutation Thomas Pudlarz, Medical Oncologist and Head of the pancreatic care pathway within the 'Interception' program at the Gustave-Roussy Institute. For decades, pancreatic cancer has remained one of oncology's most formidable challenges.
Despite major advances in immunotherapy and precision medicine, treatment for pancreatic cancer remains elusive. The emergence of an experimental targeted therapy is "one of the first improvements in many years" for a disease tha For the complete material, the listing points back to the source inside the network.